Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
about
The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare CancersCisplatin in cancer therapy: molecular mechanisms of actionFool's gold, lost treasures, and the randomized clinical trial.Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug AdministrationPreclinical Assessment of Low Doses of Cisplatin in the Management of Acute Promyelocytic LeukemiaNew considerations in the design of clinical trials for the treatment of acute leukemia.Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA ApprovalRegulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia CellsAn appraisal of drug development timelines in the Era of precision oncology.Role of randomized phase III trials in an era of effective targeted therapies.Study design and "evidence" in patient-oriented research.MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer.Meaningful endpoints for therapies approved for hematologic malignancies.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.When to randomize, or 'Evidence-based medicine needs medicine-based evidence'.Silencing of TGIF sensitizes MDA-MB-231 human breast cancer cells to cisplatin-induced apoptosis.Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.The importance of greater speed in drug development for advanced malignancies.Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs
P2860
Q28087174-7EB45197-59D4-44A3-A478-01A1FA26AE33Q34098163-70E9A79B-D4E7-4817-9CB6-3963396D5C15Q34669260-C254C14F-9130-48EA-A180-20A5894C8CFAQ36565598-E56D42A0-E9D5-4CAC-A402-FB419745E793Q36593474-226C585F-B320-4D70-BB37-5E7C4EEEADEBQ36641721-6B0F99AF-0E5E-4668-ADD1-CBD370C2DA1EQ36871001-97C01386-237F-43A8-ADCE-4318A8F1A48DQ37063626-D42EEC9A-4321-4A44-8D73-5C93780DBE17Q37204356-5D0B8B9C-D3AF-42B9-AAAA-5056EB403AF8Q37619700-3C57E621-072F-4229-B47E-7CE9B4123DCAQ37964935-321273D8-5484-4EC5-83DE-91E20311CC6DQ38110966-B38B9219-7E92-454D-AB50-C09746AA1399Q38938572-FA7092FB-7529-40CA-AF0D-DF0A8919660DQ38950082-9330EFFF-3B98-47F1-9915-5D1431856A74Q38996724-6B7BA8B1-3D35-4A53-A4D4-A3DA3D787213Q45384505-E6E82C9C-0E70-4683-98C6-6880B554F0FDQ49875247-E1F0B33E-19A0-4909-A867-648ED3A4A409Q50001044-B7D25922-C9C9-4FF2-8884-12D6CC32FEF9Q52618970-C7BC1087-3DDB-4E72-82DB-9BFFC0181E00Q53083460-F01D62FD-1AD0-4EB2-B155-C6C5CD298E43Q58718992-85905296-F067-4930-AFF1-C2CB8C134ACD
P2860
Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ultimate fate of oncology drug ...... on without a randomized Trial.
@en
Ultimate fate of oncology drug ...... on without a randomized Trial.
@nl
type
label
Ultimate fate of oncology drug ...... on without a randomized Trial.
@en
Ultimate fate of oncology drug ...... on without a randomized Trial.
@nl
prefLabel
Ultimate fate of oncology drug ...... on without a randomized Trial.
@en
Ultimate fate of oncology drug ...... on without a randomized Trial.
@nl
P356
P1476
Ultimate fate of oncology drug ...... on without a randomized Trial.
@en
P2093
David J Stewart
Fadi Braiteh
P304
P356
10.1200/JCO.2009.23.6018
P407
P577
2009-10-13T00:00:00Z